Various phase I/II clinical trials of systemic immunotoxin therapy for a variety of haematological malignancies have been completed or are currently in progress (Vitetta et al., 1993) . Two main target molecules, CD19 and CD22, have so far been exploited clinically for toxin delivery to malignant B cells. CD22 has proven an excellent target molecule in terms of the potency of immunotoxins made with antibodies recognising this B-cell structure (Shen et al., 1988) . However, expression of CD22 is quite heterogenous within B-cell tumours, often with only a,small percentage of tumour cells expressing this molecule. This obviously limits the value of CD22 as target molecule in the context of immunotoxinbased therapies in which delivery of toxin to all individual tumour cells is required to ensure total ablation of the neoplastic clone.
CD19 on the other hand is a pan B-cell cell-surface differentiation structure that appears early in ontogeny and is expressed by the majority of pre-B and B-cell tumours with the exception of myeloma (Ling et al., 1987) . Moreover, in general CD19 is homogeneously expressed by the vast majority of cells within a given B-cell tumour which includes B-cell non-Hodgkin's lymphoma and pre-B-cell acute lymphoblastic leukaemia (Schuurman et al., 1987) . These characteristics make CD19 an ideal target molecule for toxin delivery to malignant B cells. However, immunotoxins constructed with anti-CD19 antibodies are generally less potent than those constructed with anti-CD22 antibodies (Ghetie et al., 1988) .
Three anti-CD19 immunotoxins have been reported in clinical use. B4-bR comprises the anti-CD19 antibody B4 coupled via a disulphide linker to blocked ricin (intact ricin in which the two galactose-binding domains of the B-chain have been chemically blocked) ha been investigated in two separate phase I trials in patientA with advanced B-cell tumours (Grossbard et al., 1992 (Grossbard et al., , 1993b ) and more recently in a phase I study in patients in complete remission with B-cell lymphoma following autologous bone marrow transplantation (Grossbard et al., 1993a) . HD37-dgR is an immunotoxin comprised of deglycosylated ricin A chain coupled via a hindered disulphide linker to the anti-CDl9 antibody HD37 and has also been used in a phase I clinical study (Conry et al., 1994) . B43-PAP uses the single-chain ribosome-inactivating protein, pokeweed antiviral protein (PAP) coupled via a non-hindered disulphide bond to the B43 antibody. In formal phase I clinical trials, all three of these reagents have shown anti-tumour activity in a variable proportion of therapy-resistant patients, most notably B43-PAP in an ongoing phase I study has induced four complete responses in patients with multiply relapsed common acute lymphoblastic leukaemia (cALL). Saporin has never been targeted against CD19 in clinical trials in man though it has been used in immunotoxin form in four patients with Hodgkin's lymphoma using the anti-CD30 antibody Ber-H2 (Falini et al., 1992) , and major transient responses were observed.
We report here preclinical investigations with a new anti-CD19 immunotoxin BU12-SAPORIN which uses the singlechain ribosome-inactivating protein saporin coupled via a non-hindered disulphide bond to BU-12 antibody. BU12-SAPORIN is clearly demonstrated to be highly selective at delivering saporin only to CD19+ B-cell lines in vitro and to be therapeutically effective in vivo in a SCID mouse model of human CD19+ pre-B-cell acute lymphoblastic leukaemia. These preclinical studies provide the rationale for taking BU12-SAPORIN into a phase I clinical trial in patients with advanced therapy refractory B-cell tumours.
Materials and methods

SCID mice
Pathogen free BALB/c.C57BL/KaIgh-l/ICR scid/scid (SCID) mice of both sexes 6-10 weeks of age were produced from our own breeding colony and used in all the experimental work described here. The breeding colony is maintained under sterile conditions inside a laminar flow isolator and animals are housed on sterile bedding and provided with sterile water and food ad libitum. Animals for experimental NALM-6 and HSB-2 human leukaemia cell lines The CD19+ CD7-Pre-B leukaemia cell line NALM-6 was originally established from the peripheral blood of a 19-yearold male with non-T non-B acute lymphoblastic leukaemia (Hurwitz et al., 1979) . The CD7+ CD19-human cell line HSB-2 was originally established from peripheral blood leukaemic blasts from a 4-year-old paediatric patient with terminal T-cell acute lymphoblastic leukaemia (Adams et al., 1970) . Both NALM-6 and HSB-2 cells were maintained in the logarithmic phase of growth in culture flasks containing antibiotic-free RPMI medium (Integra Biosciences, Northum- (Ling et al., 1987 BU-12 SAPORIN immunotoxin construction BU-12 SAPORIN immunotoxin was constructed by conjugating the BU-1 2 antibody to saporin with the heterobifunctional cross linking reagent N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP) as described by Thorpe et al. (1985) . BU12-SAPORIN prepared in this way contained a non-hindered disulphide bond between antibody and saporin. Free antibody was removed from the immunoconjugates by carboxymethyl-Sepharose (Sigma) cation exchange chromatography as described previously (Lambert et al., 1985) . Purified BU12-SAPORIN was dialysed into phosphatebuffered saline (PBS) pH 7.2, sterilised by passage through a 0.2 ltm filter and stored deep frozen in aliquots at -80°C.
HB2-Sap immunotoxin
The preparation, characteristics and performance of the anti-CD7 immunotoxin HB2-Sap have been described in detail by us previously Morland et al., 1994 of 0.0069 ytg ml-'. Native BU 12 antibody used over the same concentration range had virtually no effect on protein synthesis levels in NALM-6 cells. Similarly, the irrelevant anti-CD7 immunotoxin HB2-Sap used over the same concentration range as BU12-SAPORIN had no significant effect on protein synthesis levels in NALM-6 cells. The IC50 value for saporin alone was 2.4pgml-1 and therefore the calculated increase in cytotoxicity of BU12-SAPORIN over native saporin was 347-fold. Figure 4 shows protein synthesis levels in the CD 19-CD7+ T-ALL cell line HSB-2 exposed to increasing concentrations (0.00 1 -10Ig ml -) of BU12-SAPORIN or HB2-Sap. BU12-SAPORIN did not inhibit protein synthesis in HSB-2 cells at any of the concentrations investigated. As expected, the anti-CD7 immunotoxin HB2-Sap, inhibited protein synthesis in CD7+ HSB-2 cells in a dose-dependent manner with an achieved IC50 value of 0.014 jig ml-'. 
..--'-I' I Concentration (jg ml-1 Uckun et al. (1992) . For humane purposes we painlessly killed experimental animals in these studies when they first showed signs of paralysis and the survival figures expressed thus represent survival up to this point. Figure 5 shows the direct relationship between the number of NALM-6 cells injected and survival time, with animals receiving the greatest number of cells surviving for the shortest period.
We have previously described in detail the characteristics of acute T-cell HSB-2 leukaemia in SCID mice (Morland et al., 1994) . Animals with disseminated HSB-2 leukaemia have multiorgan involvement but generally do not develop neurological problems because HSB-2 tumour cells do not infiltrate the CNS as extensively as NALM-6 cells. Animals with HSB-2 leukaemia thus tend to develop a wasting-type disease and become moribund as essential organs are infiltrated.
Therapy of SCID-NALM-6 mice with BU12-SAPORIN Figure 6a shows the survival of groups of SCID mice injected i.v. with 2 x 106 NALM-6 cells followed by sham therapy with PBS, BU12-SAPORIN, the irrelevant anti-CD7 saporin immunotoxin HB2-Sap or native BU12 antibody + saporin. Sham-treated control animals had a median survival time of 40.2 days with all animals dead within this group by 45 days. Treatment with BU12-SAPORIN led to a significant prolongation in survival (sham-treated controls vs BU12-SAPORIN therapy P = 0.000723 by log-rank analysis) of SCID-NALM-6 mice with 40% of animals alive and apparently disease free at the termination of the experiment at 110 days. Treatment with unconjugated BU12 antibody + saporin also had a significant therapeutic effect (sham-treated controls vs BU12 + saporin treatment P = 0.00413), animals within this treatment group having a median survival of 63.3 days but with all animals dead by 95 days. Comparison of the BU12-SAPORIN IT treatment group with the BU12 + saporin group by log-rank analysis revealed a significant difference between the two (P = 0.0525) with BU12-SAPORIN treatment being obviously superior. The irrelevant anti-CD7 immunotoxin HB2-SAP had no therapeutic effect in SCID-NALM-6 mice, animals within this group dying at approx- These preclinical studies with BU12-SAPORIN have clearly demonstrated the selective cytotoxicity of this immunotoxin for CD19+ but not CD19-human leukaemia cell lines. In vitro assays revealed that BU12-SAPORIN inhibited protein synthesis in CD19+ NALM-6 target cells in a dose-dependent manner but had no effect on protein synthesis levels in the CD19-T-ALL cell line HSB-2.
In therapy studies in SCID mice with disseminated CDl9+ NALM-6 leukaemia, BU12-SAPORIN had a significant therapeutic effect in comparison to PBS sham-treated animals. In contrast treatment of NALM-6-bearing SCID mice with the irrelevant anti-CD7 immunotoxin HB2-Sap had no beneficial therapeutic effect. BU12 antibody given together with saporin in a molar ratio equivalent to that found in the immunotoxin did have a positive therapeutic benefit with a prolongation in mean survival of these animals by an additional 50 days over sham-treated controls. However, (1992) reported that the anti-CD19 antibody B43 had no therapeutic effect against NALM-6 cells in SCID mice. The fact that BU12 antibody has a minimum cytotoxic effect on NALM-6 cells in vitro, and yet has a major therapeutic effect in vivo, points to the likely involvement of host effector mechanisms which might include complement-mediated killing and/or antibodydependent cellular cytotoxicity through recruitment of natural killer (NK) cells which are present in SCID mice (Dorshkind et al., 1985) . Contrary to this Ghetie et al. (1994) have demonstrated in vitro that a variety of anti-CD19 antibodies, including BU-12, inhibit protein synthesis and cellular proliferation in the CDl9+ B-cell line Daudi and have concluded that this is the major in vivo anti-tumour mechanism. However, it is clear from our in vitro studies that this effect does not occur with NALM-6 cells. Further confirmation of the absolute specificity of BU12-SAPORIN only for CD19+ cells was provided by the total lack of therapeutic effect of BU12-SAPORIN in SCID mice bearing the CD19-CD7+ T-ALL cell line HSB-2.
Functionally CD19 antigen is a membrane receptor involved in the regulation of B-cell proliferation (DeRie et al., 1989) . It is an ideal target molecule for B-cell tumours, being expressed on all human B-cell subpopulations (with the exception of plasma cells) and B-cell precursors before CD10 expression, making it the earliest B-cell differentiation structure appearing in ontogeny (Uckun et al., 1988 (Weiner, et al., 1989) , should not occur with BU 12-SAPORIN and indeed the clinical experience with other anti-CD19 immunotoxins attests to this. It has, however, been shown that the anti-CD19-blocked ricin immunotoxin B4-bR administered to B-cell lymphoma patients results in dramatic reductions in normal circulating B-cells which are obviously eliminated by the immunotoxin (Grossbard et al., 1992) . However, normal levels of circulating CD19+ B-cells were restored within 25 days following cessation of treatment. We expect that patients treated systemically with BU12-SAPORIN are also likely to show falls in normal circulating B-cells but as CD19 is not expressed on the B-cell stem cell population regeneration to within normal levels should occur rapidly. The existence of such a large pool of CD19+ normal B-cells in patients treated with BU12-SAPORIN will unfortunately provide a barrier to therapeutic effectiveness, with normal B-cells competing with malignant target cells for binding and resulting in consumption of immunotoxin. One major shortcoming of the SCID model of human pre-B-cell acute lymphoblastic leukaemia described here is the lack of a normal B-cell population that expresses human CD19. This model cannot therefore predict the effects such a normal B-cell population would have on BU12-SAPORIN pharmacokinetics and clearance in man.
Recent phase I trials with anti-CD19 immunotoxins in patients with B-cell malignancies have demonstrated activity of these therapeutics in a significant proportion of patients treated. In particular the B43-PAP immunotoxin, comprising the anti-CD19 antibody B43 coupled to the single-chain ribosome-inactivating protein pokeweed antiviral protein, has shown promising activity in cALL patients (Uckun, 1993) . The preclinical findings we have described here for BU12-SAPORIN are encouraging and provide a sound rationale for investigating the activity of BU12-SAPORIN in a formal clinical trial of patients with CD19+ B-cell tumours.
